Treating the Intersection of Infection and Inflammation

INV-102 is a unique therapeutic that enhances innate immunity while simultaneously improving wound healing.

A New Treatment for Respiratory & Ocular Diseases

Invirsa’s lead compound, INV-102, is derived from a naturally occurring small molecule that modulates the activity of three parallel enzyme systems that are critical to innate immune response. In vitro tests have already shown that INV-102 reduces cellular injury/death caused by adenovirus (the main virus associated with infectious conjunctivitis). In vivo studies have demonstrated definitive efficacy in a model of adenovirus keratoconjunctivitis. In addition, Invirsa is developing in vitro and in vivo data to support several additional indications.

Approximate breakdown of infectious causes of acute conjunctivitis
Antibiotics have no effect on 80% of acute conjunctivitis cases.

INV-102 is the solution.

Real Market Potential

Estimated 14 cases per 1000 population per year.

Dramatic Results

Robert Shalwitz, M.D.

Dr. Shalwitz is a pediatric endocrinologist with extensive background in clinical research and experience with the FDA. He has led teams to multiple successful new and supplemental drug approvals (NDAs and sNDAs) while at Abbott Laboratories and Reliant Pharmaceuticals. As one of the founders of both Akebia Therapeutics and Aerpio Therapeutics, Dr. Shalwitz participated in raising over $200 Million, including a successful public offering of Akebia.

Isaiah Shalwitz

Isaiah Shalwitz is a biostatistician and experienced program manager in pharmaceutical development. Isaiah worked in multiple aspects of pharmaceutical development during his eight-year tenure with Akebia Therapeutics. Most recently, Isaiah was the program manager for the team during non-clinical development, including IND enabling studies, of AKB-6899.

Current Investors

CincyTech Rev1 Ventures

Contact Us

Have a question? Partnerships? We’re always open to talking. Send us a message at or fill out the form below.